OpportunityTitle: Collaborations to Enhance Drug Development and Regulatory Science - Clinical Trials Optional
AdditionalInformationOnEligibility: (1) The entity is-   (A) an institution of higher education (as such term is defined in section 1001 of title 20) or a consortium of such institutions; or   (B) an organization described in section 501(c)(3) of title 26 and exempt from tax under section 501(a) of such title.(2) The entity has experienced personnel and clinical and other technical expertise in the biomedical sciences, which may include graduate training programs in areas relevant to priorities of the Critical Path Initiative.(3) The entity demonstrates they are capable of-   (A) developing and critically evaluating tools, methods, and processes- (i) to increase efficiency, predictability, and productivity or medical product development; and (ii)to more accurately identify the benefits and risks of new and existing medical products  (B) establishing partnerships and collaborations with health care practitioners and other providers of health care goods or services; pharmacists; pharmacy benefit managers and purchasers; health maintenance organizations and other managed health care organizations; health care insurers; government agencies; patients and consumers; manufacturers of prescription drugs, biological products, diagnostic technologies, and devices; and academic scientists; and   (C) securing funding for the projects of a Critical Path Public-Private Partnership from Federal and nonfederal governmental sources, foundations, and private individuals.
Description: This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.
GrantorContactEmailDescription: terrin.brown@fda.hhs.gov
GrantorContactText: Terrin Brown &lt;br/&gt;Grantor